Virtual Challenging Case Clinic:
GI Cancers

  • Get clinical insights on the latest emerging therapeutic options for your patients with GI cancers
  • Ask expert presenters for advice on your own patient cases
VCC Main image 2
Bendell Johanna 224x300 1 1

Course Director

Johanna Bendell, MD
Chief Development Officer
Director, GI Cancer Research Program
Sarah Cannon
Nashville, Tennessee


  • Welcome, Introductions, and Pre-session Survey
  • General Disease State and Treatment Guidelines
  • Expert Insights: Faculty-submitted cases
  • Case Presentation, Polling Questions, and Discussion
  • Q&A
  • Conclusion and Post-session Survey

Upcoming Webinars

Recordings From Previous Webinars
Updates from ASCO / World GI and Series Review

Daniel Catenacci, MD
University of Chicago | Chicago, Illinois
Broadcast July 15, 2021

Hot Topics in Gastric and Esophageal Cancer

David Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center
Broadcast June 17, 2021


Current Status: Small Bowel, Pancreatic, Anal, and Biliary Cancers

Andrew Ko, MD
UCSF Health l San Francisco, California
Broadcast May 20, 2021


Genetics & Promising Biomarkers in GI Cancer

Mike Pishvaian, MD, PhD
Johns Hopkins Medicine | Washington, District of Columbia
Broadcast April 15, 2021

Colorectal Cancer: Emerging Role of BRAF, IO, and Novel Therapeutics

Mike Overman, MD
MD Anderson Cancer Center | Houston, Texas
Broadcast March 11, 2021

Updates from ASCO GI Symposium

Tanios Bekaii-Saab, MD, FACP
Mayo Clinic | Phoenix, Arizona
Broadcast February 18, 2021

This activity is supported by independent educational grants from Ipsen Biopharmaceuticals, Merck & Co., and Taiho Oncology, Inc.

Target Audience

The target audience for this activity is clinicians who treat patients with gastrointestinal cancers (gastroenterologists, hepatologists, medical oncologists, surgical oncologists, GI surgeons, oncology nurses and nurse practitioners, interventional radiologists, oncology pharmacists).

Learning Objectives
  • Evaluate best available evidence regarding treatment of GI cancer
  • Assess the clinical implications of emerging clinical trial data regarding treatment approaches for patients with GI cancer
  • Develop strategies to address complicated GI cancer cases
Continuing Education

UNMC Joint Accreditation Logo December2020 1

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  
Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.